Mar 23, 2021 / 10:30AM GMT
Peter Jonathan Butterfield - Alliance Pharma plc - CEO & Executive Director
Thank you very much, and good morning, everybody. I'm Pete Butterfield, CEO, and I'm here online with Andrew Franklin, our CFO, this morning. So firstly, I hope you're all keeping well, and thank you for attending this analyst meeting. Before we start the presentation, can I just check that you've all got copies of today's slides? And if not, you can find a copy on the Investors section of our website.
So I'm delighted to be able to share with you our 2020 results this morning, and despite the challenges thrown up by the COVID pandemic, I'm very pleased to report that the business has developed strongly. Robust underlying trading and strong pretax cash flow have been complemented by a strong underlying development of the business, including great progress with Kelo-cote, our #1 brand; the Nizoral integration now being substantially complete; and the successful completion of our second largest deal ever with the exciting acquisition of the Amberen brand at the end of the year.
Operationally, we're also able to
Full Year 2020 Alliance Pharma PLC Earnings Call Transcript
Mar 23, 2021
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers